Search - tctmd.com

Displaying 221 - 240 of 379

Sort: Relevancy | Date

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

August 31, 2020

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

News Daily News

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

Yael L. Maxwell

August 19, 2020

Could Statins Curb Fatal or Severe COVID-19? Some Clues

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

News Daily News

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

July 28, 2020

Race and Gender Bias May Sway Decisions in Advanced HF Care

News Daily News

Race and Gender Bias May Sway Decisions in Advanced HF Care

July 21, 2020

PAD Patients Undertreated With Statins Despite Elevated CV Risk

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

July 13, 2020

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

March 04, 2020

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

February 14, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.